THERAPEUTIC AREA

UNS is developing innovative therapeutics for Alzheimer’s and other neurodegenerative diseases.

 

Why?

 

There is a high unmet need in CNS and neurodegenerative disease space. Disorders of the Central Nervous System (CNS) make up the largest therapeutic area by drug spend in the world today. Despite the dominant share of global drug spend, there exists a significant unmet medical need. This is largely due to the devastating impact on the lives of those chronically affected, the loss of productivity due to decreasing physical and mental functioning over time, and the overwhelming burden on family and friend caregivers. Globally, the economic burden of CNS is estimated at over $2 trillion dollars annually. Within CNS, neurodegenerative diseases have a high unmet need with many of the current therapeutic solutions being symptomatic, failing to treat the underlying cause of their target diseases. Also, the aging population is driving higher needs for chronic conditions that include pain and neurodegenerative diseases such as Alzheimer’s and Parkinson’s. There are currently no cures for many of the neurodegenerative diseases that exist.